| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | Oncologist | 2009 | 1.53 |
| 2 | Time spent for activation of non-profit studies in oncology in Italy. | PLoS One | 2010 | 0.83 |
| 3 | Synthesis and cytotoxic evaluation of novel spirohydantoin derivatives of the dihydrothieno[2,3-b]naphtho-4,9-dione system. | J Med Chem | 2005 | 0.78 |